Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors

  • ACS Med Chem Lett. 2013 Jul 12;4(8):806-10. doi: 10.1021/ml400203d.
Jingrong Li  1 ,  Nan Wu  2 ,  Yuanxin Tian  1 ,  Jiajie Zhang  1 ,  Shuguang Wu  1
Affiliations
  • 1. School of Pharmaceutical Sciences, Southern Medical University , 1838 North Guangzhou Boulevard, Guangzhou 510515, China.
  • 2. Department of Neurosurgery, Southwest Hospital, Third Military Medical University , Chongqing 400038, China.
PMID: 24900750 DOI: 10.1021/ml400203d
Abstract

A series of novel aminopyridyl/pyrazinyl-substituted spiro[indoline-3,4'-piperidine]-2-ones were designed, synthesized, and tested in various in vitro/in vivo pharmacological and antitumor assays. 6-[6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-pyridyl]-1'-methylspiro[indoline-3,4'-piperidine]-2-one (compound 5b or SMU-B) was identified as a potent, highly selective, well-tolerated, and orally efficacious c-Met/ALK dual inhibitor, which showed pharmacodynamics effect by inhibiting c-Met phosphorylation in vivo and significant tumor growth inhibitions (>50%) in GTL-16 human gastric carcinoma xenograft models.

Keywords
Hepatocyte growth factor receptor (HGFR or c-Met); aminopyrazine; aminopyridine; anaplastic lymphoma kinase (ALK); cancer; inhibitor; small molecule; spiro[indoline-3,4′-piperidine]-2-one.
Products